Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
Follow IMMP
Prima BioMed Ltd (IMMP) Piotroski F-score
Prima BioMed Ltd's Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | 1.00 |
| FY2025 | 2 | (3.00) |
| FY2024 | 5 | 2.00 |
| FY2023 | 3 | (2.00) |
| FY2022 | 5 | 2.00 |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | 3.00 |
| FY2019 | 1 | (2.00) |
| FY2018 | 3 | (1.00) |
| FY2017 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (68.06%) | (34.02%) | Fail | 0 |
| Positive operating cash flow | (37.64m) | (40.18m) | Fail | 0 |
| Rising return on assets | (68.06%) | (34.02%) | Fail | 0 |
| Cash flow above net income | 16.18m | (398.60k) | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 5.69 | 11.69 | Fail | 0 |
| No new shares issued | 7,357,900 | 7,279,100 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.21 | 0.06 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ABVC ABVC BioPharma, Inc. compare | 6 |
| BYSI BeyondSpring Inc. compare | 5 |
| EVAX Evaxion A/S - Sponsored ADR compare | 5 |
| CYAD Celyad SA compare | 3 |
| IMMP Prima BioMed Ltd | 3 |
| MCRB Seres Therapeutics, Inc. compare | — |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover